Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2022 Earnings Conference Call May 4, 2022 5:00 PM ET

Company Participants

Todd Friedman - Director, IR

Christian Henry - President and Chief Executive Officer

Susan Kim - Chief Financial Officer

Conference Call Participants

Dan Brennan - Cowan

David Westenberg - Piper Sandler

Tejas Savant - Morgan Stanley

Kyle Mikson - Canaccord

Operator

Good day and welcome to the PacBio First Quarter Fiscal 2022 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]

I would now like to turn the conference over to Todd Friedman, Director of Investor Relations. Please go ahead.

Todd Friedman

Thank you. Good afternoon, and welcome to PacBio's first quarter 2022 earnings conference call.

Earlier today, we issued a press release outlining the financial results we will be discussing on today's call. A copy of which is available in the Investors section of our website at www.pacb.com, or is furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov.

With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer.

Before we begin, I'd like to remind you that on today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, expectations, intention, guidance, expectations for, including advantages and capabilities in connection with new products, technology and software development and launches, and the anticipated timing of such development and launches, expectations resulting from continued building and enablement of HiFi ecosystem, expectations with respect to our partnerships and collaborations, estimates, intentions, and plans to use the company's cash and investments to fund current development and commercialization initiatives until achieving positive operating cash flow without the need to raise additional capital and other information. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including challenges inherent in developing manufacturing, launching marketing, selling new products and achieving anticipated new sales, competition, unanticipated increases in costs or expenses, interruptions, or delays in the supply of components or materials for or manufacturing of PacBio products and products under development, potential product performance and quality issues and potential delays in development timelines. The impact of the COVID-19 pandemic risks associated with international operations among others.

These risks and uncertainties as well as other risks and uncertainties are more fully described in our press release earlier today and in our Form 8-K, Form 10-Q and Form 10-K and other filings with the SEC. We disclaim any obligation to update or revise these forward-looking statements except as required by law.